Oculis to Present Positive Phase 2 Biomarker Analyses for Privosegtor in Optic Neuritis

Oculis is scheduled to present late-breaking Phase 2 ACUITY biomarker analyses for Privosegtor, a treatment for optic neuritis, at the 10th Joint ACTRIMS-ECTRIMS Meeting. Privosegtor has previously received Breakthrough Therapy designation from the FDA and Priority Medicines (PRIME) designation from the EMA, and is currently undergoing two registrational trials.